Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.18
23.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
PP&E Gross
Catalyst Pharmaceuticals Inc
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
PP&E Gross
$3.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
25%
|
CAGR 10-Years
43%
|
|
|
Abbvie Inc
NYSE:ABBV
|
PP&E Gross
$5.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Catalyst Pharmaceuticals Inc
Glance View
Catalyst Pharmaceuticals Inc., a biopharmaceutical company founded with a determined focus on developing innovative therapies, has systematically carved out a niche in the treatment of rare neuromuscular and neurological diseases. Headquartered in Coral Gables, Florida, the company emerged as a lifeline for patients grappling with these debilitating conditions, particularly targeting those with limited treatment options. At the heart of Catalyst’s business model is its flagship product, Firdapse (amifampridine), a pioneering medication approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). This niche focus allows Catalyst to not only address unmet medical needs but also to navigate a less crowded competitive landscape, where larger pharmaceutical giants often overlook rare conditions. Catalyst Pharmaceuticals' revenue stream is primarily derived from the commercial sales of Firdapse, which has gained traction in the rare disease market due to its status as a first-line treatment. The company adopts a strategic approach by exclusively concentrating on rare diseases, benefiting from incentives such as orphan drug designations, which often include extended market exclusivity, tax credits, and potential grants. This strategy is bolstered by an experienced management team that adeptly leverages Catalyst’s research capabilities and regulatory know-how, ensuring a robust pipeline poised for future growth. By maintaining strong relationships with healthcare providers and patient advocacy groups, Catalyst Pharmaceuticals reinforces its commitment to patient-centric solutions, enabling both sustained market presence and organic growth within its specialized field.
See Also
What is Catalyst Pharmaceuticals Inc's PP&E Gross?
PP&E Gross
3.6m
USD
Based on the financial report for Jun 30, 2024, Catalyst Pharmaceuticals Inc's PP&E Gross amounts to 3.6m USD.
What is Catalyst Pharmaceuticals Inc's PP&E Gross growth rate?
PP&E Gross CAGR 10Y
43%
Over the last year, the PP&E Gross growth was -5%. The average annual PP&E Gross growth rates for Catalyst Pharmaceuticals Inc have been -4% over the past three years , 25% over the past five years , and 43% over the past ten years .
You don't have any saved screeners yet
